Anabolic Steroid Control Act of 2004
Legislative Activity
Stay on top of the latest movement without scrolling through every action
Became Public Law No: 108-358.
October 22, 2004
View full timeline
Introduced in Senate
March 11, 2004
Read twice and referred to the Committee on the Judiciary.
March 11, 2004
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
September 30, 2004
Committee on the Judiciary. Reported by Senator Hatch with an amendment in the nature of a substitute. Without written report.
September 30, 2004
Placed on Senate Legislative Calendar under General Orders. Calendar No. 750.
September 30, 2004
Measure laid before Senate by unanimous consent. (consideration: CR 10/7/2004 S10606-10609; text of measure as reported in Senate: CR 10/7/2004 S10606-10608)
October 6, 2004
The committee substitute as amended agreed to by Unanimous Consent.
October 6, 2004
Passed Senate with an amendment by Unanimous Consent.
October 6, 2004
Received in the House.
October 6, 2004 • 10:35 PM
Message on Senate action sent to the House.
October 6, 2004
Held at the desk.
October 6, 2004 • 11:08 PM
Considered by unanimous consent. (consideration: CR H9010-9011)
October 8, 2004 • 10:46 PM
Mr. Cannon asked unanimous consent to take from the Speaker's table and consider.
October 8, 2004 • 10:46 PM
Passed/agreed to in House: On passage Passed without objection.(text: CR H9010-9011)
October 8, 2004 • 10:47 PM
On passage Passed without objection. (text: CR H9010-9011)
October 8, 2004 • 10:47 PM
Motion to reconsider laid on the table Agreed to without objection.
October 8, 2004 • 10:47 PM
Presented to President.
October 13, 2004
Signed by President.
October 22, 2004
Became Public Law No: 108-358.
October 22, 2004
Floor Debate
11 membersWhat members said about S. 2195 on the floor




+6
Floor Debate
11 membersWhat members said about S. 2195 on the floor
Mr. President, I ask unanimous consent that the Committee on Finance be authorized to meet during the session on Tuesday, September 14, 2004, at 10 a.m., to hear testimony on ``Implementing the…
Mr. President, I ask unanimous consent that the Committee on Energy and Natural Resources be authorized to meet during the session of the Senate on Thursday, September 30 at 10:30 a.m. to receive…
Mr. President, I ask unanimous consent that the Committee on Commerce, Science, and Transportation be authorized to meet on Tuesday, September 21, 2004, at 9:30 a.m. on Oceans Commission. Mr.…
Mr. President, I ask unanimous consent that the Committee on Armed Services be authorized to meet during the session of the Senate on September 9, 2004, at 9:30 a.m., in open session to receive…
Will the Senator yield? I too would like to thank the senior Senator from Illinois for working with the senior Senator from Delaware and with me on this legislation. I would also like to clarify,…
Show 7 more
The purpose of S. 2195, The Anabolic Steroid Control Act of 2004, is to address the abuse of steroids by athletes and, especially, by youngsters and teenagers. Some substances marketed as dietary…
Mr. President, I am pleased that the Senate has passed S. 2195, the Anabolic Steroid Control Act, and I commend my colleagues Senators Hatch and Biden for their commitment to this important…
Will the Senator yield for a question? I commend the senior Senator from Utah, as well as the senior Senator from Delaware, for their leadership on this legislation, and for working with me and the…
Will the Senator yield for a question? I would like to commend the senior Senator from Delaware and the chairman of the Judiciary Committee, the senior Senator from Utah, for their leadership on this…
Mr. President, I ask unanimous consent that the Senate proceed to the immediate consideration of Calendar No. 750, S. 2195. I ask unanimous consent that the technical amendment at the desk be agreed…
Mr. Speaker, I ask unanimous consent to take from the Speaker's table the Senate bill (S. 2195) to amend the Controlled Substances Act to clarify the definition of anabolic steroids and to provide…
Mr. Speaker, I ask unanimous consent that all Members may have 5 legislative days within which to revise and extend their remarks and include extraneous material on S. 2195.
Bill Text
5 versions available
[Congressional Bills 108th Congress]
[From the U.S. Government Publishing Office]
[S. 2195 Enrolled Bill (ENR)]
S.2195
One Hundred Eighth Congress
of the
United States of America
AT THE SECOND SESSION
Begun and held at the City of Washington on Tuesday,
the twentieth day of January, two thousand and four
An Act
To amend the Controlled Substances Act to clarify the definition of
anabolic steroids and to provide for research and education activities
relating to steroids and steroid precursors.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Anabolic Steroid Control Act of
2004''.
SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES ACT.
(a) Definitions.--Section 102 of the Controlled Substances Act (21
U.S.C. 802) is amended--
(1) in paragraph (41)--
(A) by realigning the margin so as to align with paragraph
(40); and
(B) by striking subparagraph (A) and inserting the
following:
``(A) The term `anabolic steroid' means any drug or hormonal
substance, chemically and pharmacologically related to testosterone
(other than estrogens, progestins, corticosteroids, and
dehydroepiandrosterone), and includes--
``(i) androstanediol--
``(I) 3b,17b-dihydroxy-5a-androstane; and
``(II) 3a,17b-dihydroxy-5a-androstane;
``(ii) androstanedione (5a-androstan-3,17-dione);
``(iii) androstenediol--
``(I) 1-androstenediol (3b,17b-dihydroxy-5a-androst-1-ene);
``(II) 1-androstenediol (3a,17b-dihydroxy-5a-androst-1-
ene);
``(III) 4-androstenediol (3b,17b-dihydroxy-androst-4-ene);
and
``(IV) 5-androstenediol (3b,17b-dihydroxy-androst-5-ene);
``(iv) androstenedione--
``(I) 1-androstenedione ([5a]-androst-1-en-3,17-dione);
``(II) 4-androstenedione (androst-4-en-3,17-dione); and
``(III) 5-androstenedione (androst-5-en-3,17-dione);
``(v) bolasterone (7a,17a-dimethyl-17b-hydroxyandrost-4-en-3-
one);
``(vi) boldenone (17b-hydroxyandrost-1,4,-diene-3-one);
``(vii) calusterone (7b,17a-dimethyl-17b-hydroxyandrost-4-en-3-
one);
``(viii) clostebol (4-chloro-17b-hydroxyandrost-4-en-3-one);
``(ix) dehydrochloromethyltestosterone (4-chloro-17b-hydroxy-
17a-methyl-androst-1,4-dien-3-one);
``(x) <triangle>1-dihydrotestosterone (a.k.a. `1-testosterone')
(17b-hydroxy-5a-androst-1-en-3-one);
``(xi) 4-dihydrotestosterone (17b-hydroxy-androstan-3-one);
``(xii) drostanolone (17b-hydroxy-2a-methyl-5a-androstan-3-
one);
``(xiii) ethylestrenol (17a-ethyl-17b-hydroxyestr-4-ene);
``(xiv) fluoxymesterone (9-fluoro-17a-methyl-11b,17b-
dihydroxyandrost-4-en-3-one);
``(xv) formebolone (2-formyl-17a-methyl-11a,17b-
dihydroxyandrost-1,4-dien-3-one);
``(xvi) furazabol (17a-methyl-17b-hydroxyandrostano[2,3-c]-
furazan);
``(xvii) 13b-ethyl-17a-hydroxygon-4-en-3-one;
``(xviii) 4-hydroxytestosterone (4,17b-dihydroxy-androst-4-en-
3-one);
``(xix) 4-hydroxy-19-nortestosterone (4,17b-dihydroxy-estr-4-
en-3-one);
``(xx) mestanolone (17a-methyl-17b-hydroxy-5a-androstan-3-one);
``(xxi) mesterolone (1a-methyl-17b-hydroxy-[5a]-androstan-3-
one);
``(xxii) methandienone (17a-methyl-17b-hydroxyandrost-1,4-dien-
3-one);
``(xxiii) methandriol (17a-methyl-3b,17b-dihydroxyandrost-5-
ene);
``(xxiv) methenolone (1-methyl-17b-hydroxy-5a-androst-1-en-3-
one);
``(xxv) 17a-methyl-3b, 17b-dihydroxy-5a-androstane;
``(xxvi) 17a-methyl-3a,17b-dihydroxy-5a-androstane;
``(xxvii) 17a-methyl-3b,17b-dihydroxyandrost-4-ene.
``(xxviii) 17a-methyl-4-hydroxynandrolone (17a-methyl-4-
hydroxy-17b-hydroxyestr-4-en-3-one);
``(xxix) methyldienolone (17a-methyl-17b-hydroxyestra-4,9(10)-
dien-3-one);
``(xxx) methyltrienolone (17a-methyl-17b-hydroxyestra-4,9-11-
trien-3-one);
``(xxxi) methyltestosterone (17a-methyl-17b-hydroxyandrost-4-
en-3-one);
``(xxxii) mibolerone (7a,17a-dimethyl-17b-hydroxyestr-4-en-3-
one);
``(xxxiii) 17a-methyl-<triangle>1-dihydrotestosterone (17b-
hydroxy-17a-methyl-5a-androst-1-en-3-one) (a.k.a. `17-a-methyl-1-
testosterone');
``(xxxiv) nandrolone (17b-hydroxyestr-4-en-3-one);
``(xxxv) norandrostenediol--
``(I) 19-nor-4-androstenediol (3b, 17b-dihydroxyestr-4-
ene);
``(II) 19-nor-4-androstenediol (3a, 17b-dihydroxyestr-4-
ene);
``(III) 19-nor-5-androstenediol (3b, 17b-dihydroxyestr-5-
ene); and
``(IV) 19-nor-5-androstenediol (3a, 17b-dihydroxyestr-5-
ene);
``(xxxvi) norandrostenedione--
``(I) 19-nor-4-androstenedione (estr-4-en-3,17-dione); and
``(II) 19-nor-5-androstenedione (estr-5-en-3,17-dione;
``(xxxvii) norbolethone (13b,17a-diethyl-17b-hydroxygon-4-en-3-
one);
``(xxxviii) norclostebol (4-chloro-17b-hydroxyestr-4-en-3-one);
``(xxxix) norethandrolone (17a-ethyl-17b-hydroxyestr-4-en-3-
one);
``(xl) normethandrolone (17a-methyl-17b-hydroxyestr-4-en-3-
one);
``(xli) oxandrolone (17a-methyl-17b-hydroxy-2-oxa-[5a]-
androstan-3-one);
``(xlii) oxymesterone (17a-methyl-4,17b-dihydroxyandrost-4-en-
3-one);
``(xliii) oxymetholone (17a-methyl-2-hydroxymethylene-17b-
hydroxy-[5a]-androstan-3-one);
``(xliv) stanozolol (17a-methyl-17a-hydroxy-[5a]-androst-2-
eno[3,2-c]-pyrazole);
``(xlv) stenbolone (17b-hydroxy-2-methyl-[5a]-androst-1-en-3-
one);
``(xlvi) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-
dien-17-oic acid lactone);
``(xlvii) testosterone (17b-hydroxyandrost-4-en-3-one);
``(xlviii) tetrahydrogestrinone (13b,17a-diethyl-17b-
hydroxygon-4,9,11-trien-3-one);
``(xlix) trenbolone (17b-hydroxyestr-4,9,11-trien-3-one); and
``(xlx) any salt, ester, or ether of a drug or substance
described in this paragraph.
The substances excluded under this subparagraph may at any time be
scheduled by the Attorney General in accordance with the authority and
requirements of subsections (a) through (c) of section 201.''; and
(2) in paragraph (44), by inserting ``anabolic steroids,''
after ``marihuana,''.
(b) Authority and Criteria for Classification.--Section 201(g) of
the Controlled Substances Act (21 U.S.C. 811(g)) is amended--
(1) in paragraph (1), by striking ``substance from a schedule
if such substance'' and inserting ``drug which contains a
controlled substance from the application of titles II and III of
the Comprehensive Drug Abuse Prevention and Control Act (21 U.S.C.
802 et seq.) if such drug''; and
(2) in paragraph (3), by adding at the end the following:
``(C) Upon the recommendation of the Secretary of Health and
Human Services, a compound, mixture, or preparation which contains
any anabolic steroid, which is intended for administration to a
human being or an animal, and which, because of its concentration,
preparation, formulation or delivery system, does not present any
significant potential for abuse.''.
(c) Anabolic Steroids Control Act.--Section 1903 of the Anabolic
Steroids Control Act of 1990 (Public Law 101-647) is amended--
(1) by striking subsection (a); and
(2) by redesignating subsections (b) and (c) as subsections (a)
and (b), respectively.
(d) Effective Date.--The amendments made by this section shall take
effect 90 days after the date of enactment of this Act.
SEC. 3. SENTENCING COMMISSION GUIDELINES.
The United States Sentencing Commission shall--
(1) review the Federal sentencing guidelines with respect to
offenses involving anabolic steroids;
(2) consider amending the Federal sentencing guidelines to
provide for increased penalties with respect to offenses involving
anabolic steroids in a manner that reflects the seriousness of such
offenses and the need to deter anabolic steroid trafficking and
use; and
(3) take such other action that the Commission considers
necessary to carry out this section.
SEC. 4. PREVENTION AND EDUCATION PROGRAMS.
(a) In General.--The Secretary of Health and Human Services
(referred to in this Act as the ``Secretary'') shall award grants to
public and nonprofit private entities to enable such entities to carry
out science-based education programs in elementary and secondary
schools to highlight the harmful effects of anabolic steroids.
(b) Eligibility.--
(1) Application.--To be eligible for grants under subsection
(a), an entity shall prepare and submit to the Secretary an
application at such time, in such manner, and containing such
information as the Secretary may require.
(2) Preference.--In awarding grants under subsection (a), the
Secretary shall give preference to applicants that intend to use
grant funds to carry out programs based on--
(A) the Athletes Training and Learning to Avoid Steroids
program;
(B) The Athletes Targeting Healthy Exercise and Nutrition
Alternatives program; and
(C) other programs determined to be effective by the
National Institute on Drug Abuse.
(c) Use of Funds.--Amounts received under a grant under subsection
(a) shall be used for education programs that will directly communicate
with teachers, principals, coaches, as well as elementary and secondary
school children concerning the harmful effects of anabolic steroids.
(d) Authorization of Appropriations.--There is authorized to be
appropriated to carry out this section, $15,000,000 for each of fiscal
years 2005 through 2010.
SEC. 5. NATIONAL SURVEY ON DRUG USE AND HEALTH.
(a) In General.--The Secretary of Health and Human Services shall
ensure that the National Survey on Drug Use and Health includes
questions concerning the use of anabolic steroids.
(b) Authorization of Appropriations.--There is authorized to be
appropriated to carry out this section, $1,000,000 for each of fiscal
years 2005 through 2010.
Speaker of the House of Representatives.
Vice President of the United States and
President of the Senate.